Article

First glaucoma risk calculator set to debut

San Francisco - A newly developed risk calculator will make therapeutic decision-making for patients with ocular hypertension a little more straightforward, said Robert N. Weinreb, MD, director, Hamilton Glaucoma Center, and distinguished professor of ophthalmology, University of California, San Diego.

San Francisco - A newly developed risk calculator will make therapeutic decision-making for patients with ocular hypertension a little more straightforward, said Robert N. Weinreb, MD, director, Hamilton Glaucoma Center, and distinguished professor of ophthalmology, University of California, San Diego.

Dr. Weinreb chaired a panel of experts who developed the risk calculator based on data collected in the Ocular Hypertension Treatment Study. It will be described in an upcoming article in the Oct. 8, 2005 issue of Archives of Ophthalmology and discussed at the annual meeting of the American Academy of Ophthalmology in Chicago, Oct. 15 to 18.

Using a slide rule-type device, clinicians will be able to input individual patient risk factor data to calculate the risk of converting from ocular hypertension to glaucoma over the next 5 years. By consensus the panel decided that monitoring would be appropriate for patients with a calculated progression risk of <5%, consideration of treatment with a patient-provider discussion of the risks and benefits was recommended for individuals determined to have a 5% to 15% risk of progressing to glaucoma, while treatment is recommended for those with higher levels of risk.

Nevertheless, the risk calculator for estimating global risk should be used an adjunct to and not as a substitute for clinical experience and judgment, and each physician is likely to have his or her own threshold for treatment.

“Other factors such as the patient’s overall health status, life expectancy, and commitment to treatment should also be weighed against potential adverse events and cost of treatment,” Dr. Weinreb said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.